RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.31
+1.55%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.30
From 52W high−48.02%
Volume217035.00
Market cap$59.12M
P/E (TTM)—
P/S (TTM)29.9x
Div yield—
Key dataNov 4, 2026
Open
$1.30
From 52W high
−48.02%
Volume
217035.00
Market cap
$59.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
P/E (TTM)
—
RSI (14)
46.0
MomentumView details →
1D Return
+1.55%
YTD Return
+54.74%
SummaryUpdated Jun 1, 2026
RenovoRx, Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Los Altos, California. The company went public in August 2021 and focuses on developing innovative therapies for treating solid tumors, particularly pancreatic cancer. RenovoRx has developed a unique approach combining drug delivery devices with chemotherapy medications to improve treatment outcomes while reducing side effects for cancer patients.
Similar companies
Latest newsMore news →
RenovoRx announced that it will release its third-quarter 2026 financial results and business highlights after market close on November 5, 2026.14d agoRenovoRx, Inc. announced that the first patient was enrolled in the University of Vermont-sponsored PRISM-TAMP trial, which is evaluating TAMP before surgical resection in borderline resectable pancreatic cancer.29d agoRenovoRx announced a peer-reviewed publication highlighting the potential of its TAMP platform to improve chemotherapeutic delivery for locally advanced pancreatic cancer.35d ago